Alaunos Therapeutics, Inc.: Form 8-K, filed Oct 13, 2026

• Item 1.01 Entry into a material agreement
• Item 2.01 Completion of an acquisition or disposition
• Item 3.02 Unregistered sale of equity
• Item 5.02 Departure or appointment of officers or directors
• Item 5.03 Amendment to articles or bylaws
• Item 7.01 Regulation FD disclosure
• Item 9.01 Financial statements and exhibits

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.